Expression of the Insulin-like Growth Factor-I Receptor in Primary Breast Cancer and Lymph Node Metastases

Correlations with Estrogen Receptors α and β

M. Koda, S. Sulkowski, C. Garofalo, L. Kanczuga-Koda, M. Sulkowska, E. Surmacz

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Numerous laboratory studies and some epidemiological data have suggested the involvement of the insulin-like growth factor-I receptor (IGF-IR) in breast cancer development and progression. However, data on IGF-IR expression in human tissues, including breast cancer sections, are limited and often inconsistent. We therefore examined by immunohistochemistry the expression of IGF-IR in primary tumors and breast cancer metastases to lymph nodes, and correlated IGF-IR positivity with estrogen receptor (ER) status and selected clinicopathological features. We found that 1) IGF-IR was expressed in primary tumors as well as in lymph node metastases, but the expression in primary tumors was more frequent (56% vs. 44.4%); 2) IGF-IR expression in primary tumors was associated with negative node status (p <0.033); 3) in node-negative primary tumors, IGF-IR positively correlated with ERβ (p <0.008; r = 0.538), but not with ERα, tumor size or grade; 4) both IGF-IR-positive and IGF-IR-negative primary tumors were found to produce IGF-IR-positive as well as IGF-IR-negative metastases; 5) in metastases, IGF-IR expression did not associate with ERα, ERβ or any of the studied pathobiological markers. The results suggest that IGF-IR could become a viable pharmaceutical target in breast cancer therapy, but such therapy should be based on IGF-IR assessment in primary tumor and metastasis in each potential patient.

Original languageEnglish
Pages (from-to)794-801
Number of pages8
JournalHormone and Metabolic Research
Volume35
Issue number11-12
DOIs
Publication statusPublished - Nov 2003

Fingerprint

IGF Type 1 Receptor
Estrogen Receptors
Lymph Nodes
Breast Neoplasms
Neoplasm Metastasis
Tumors
Neoplasms

Keywords

  • Breast Cancer
  • Estrogen Receptor α
  • Estrogen Receptor β
  • Insulin-like Growth Factor-1 receptor
  • Lymph Node Metastasis

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Expression of the Insulin-like Growth Factor-I Receptor in Primary Breast Cancer and Lymph Node Metastases : Correlations with Estrogen Receptors α and β. / Koda, M.; Sulkowski, S.; Garofalo, C.; Kanczuga-Koda, L.; Sulkowska, M.; Surmacz, E.

In: Hormone and Metabolic Research, Vol. 35, No. 11-12, 11.2003, p. 794-801.

Research output: Contribution to journalArticle

@article{1451dece058c47df8e0b80f9c3a5ec3c,
title = "Expression of the Insulin-like Growth Factor-I Receptor in Primary Breast Cancer and Lymph Node Metastases: Correlations with Estrogen Receptors α and β",
abstract = "Numerous laboratory studies and some epidemiological data have suggested the involvement of the insulin-like growth factor-I receptor (IGF-IR) in breast cancer development and progression. However, data on IGF-IR expression in human tissues, including breast cancer sections, are limited and often inconsistent. We therefore examined by immunohistochemistry the expression of IGF-IR in primary tumors and breast cancer metastases to lymph nodes, and correlated IGF-IR positivity with estrogen receptor (ER) status and selected clinicopathological features. We found that 1) IGF-IR was expressed in primary tumors as well as in lymph node metastases, but the expression in primary tumors was more frequent (56{\%} vs. 44.4{\%}); 2) IGF-IR expression in primary tumors was associated with negative node status (p <0.033); 3) in node-negative primary tumors, IGF-IR positively correlated with ERβ (p <0.008; r = 0.538), but not with ERα, tumor size or grade; 4) both IGF-IR-positive and IGF-IR-negative primary tumors were found to produce IGF-IR-positive as well as IGF-IR-negative metastases; 5) in metastases, IGF-IR expression did not associate with ERα, ERβ or any of the studied pathobiological markers. The results suggest that IGF-IR could become a viable pharmaceutical target in breast cancer therapy, but such therapy should be based on IGF-IR assessment in primary tumor and metastasis in each potential patient.",
keywords = "Breast Cancer, Estrogen Receptor α, Estrogen Receptor β, Insulin-like Growth Factor-1 receptor, Lymph Node Metastasis",
author = "M. Koda and S. Sulkowski and C. Garofalo and L. Kanczuga-Koda and M. Sulkowska and E. Surmacz",
year = "2003",
month = "11",
doi = "10.1055/s-2004-814152",
language = "English",
volume = "35",
pages = "794--801",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Georg Thieme Verlag",
number = "11-12",

}

TY - JOUR

T1 - Expression of the Insulin-like Growth Factor-I Receptor in Primary Breast Cancer and Lymph Node Metastases

T2 - Correlations with Estrogen Receptors α and β

AU - Koda, M.

AU - Sulkowski, S.

AU - Garofalo, C.

AU - Kanczuga-Koda, L.

AU - Sulkowska, M.

AU - Surmacz, E.

PY - 2003/11

Y1 - 2003/11

N2 - Numerous laboratory studies and some epidemiological data have suggested the involvement of the insulin-like growth factor-I receptor (IGF-IR) in breast cancer development and progression. However, data on IGF-IR expression in human tissues, including breast cancer sections, are limited and often inconsistent. We therefore examined by immunohistochemistry the expression of IGF-IR in primary tumors and breast cancer metastases to lymph nodes, and correlated IGF-IR positivity with estrogen receptor (ER) status and selected clinicopathological features. We found that 1) IGF-IR was expressed in primary tumors as well as in lymph node metastases, but the expression in primary tumors was more frequent (56% vs. 44.4%); 2) IGF-IR expression in primary tumors was associated with negative node status (p <0.033); 3) in node-negative primary tumors, IGF-IR positively correlated with ERβ (p <0.008; r = 0.538), but not with ERα, tumor size or grade; 4) both IGF-IR-positive and IGF-IR-negative primary tumors were found to produce IGF-IR-positive as well as IGF-IR-negative metastases; 5) in metastases, IGF-IR expression did not associate with ERα, ERβ or any of the studied pathobiological markers. The results suggest that IGF-IR could become a viable pharmaceutical target in breast cancer therapy, but such therapy should be based on IGF-IR assessment in primary tumor and metastasis in each potential patient.

AB - Numerous laboratory studies and some epidemiological data have suggested the involvement of the insulin-like growth factor-I receptor (IGF-IR) in breast cancer development and progression. However, data on IGF-IR expression in human tissues, including breast cancer sections, are limited and often inconsistent. We therefore examined by immunohistochemistry the expression of IGF-IR in primary tumors and breast cancer metastases to lymph nodes, and correlated IGF-IR positivity with estrogen receptor (ER) status and selected clinicopathological features. We found that 1) IGF-IR was expressed in primary tumors as well as in lymph node metastases, but the expression in primary tumors was more frequent (56% vs. 44.4%); 2) IGF-IR expression in primary tumors was associated with negative node status (p <0.033); 3) in node-negative primary tumors, IGF-IR positively correlated with ERβ (p <0.008; r = 0.538), but not with ERα, tumor size or grade; 4) both IGF-IR-positive and IGF-IR-negative primary tumors were found to produce IGF-IR-positive as well as IGF-IR-negative metastases; 5) in metastases, IGF-IR expression did not associate with ERα, ERβ or any of the studied pathobiological markers. The results suggest that IGF-IR could become a viable pharmaceutical target in breast cancer therapy, but such therapy should be based on IGF-IR assessment in primary tumor and metastasis in each potential patient.

KW - Breast Cancer

KW - Estrogen Receptor α

KW - Estrogen Receptor β

KW - Insulin-like Growth Factor-1 receptor

KW - Lymph Node Metastasis

UR - http://www.scopus.com/inward/record.url?scp=0346095212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346095212&partnerID=8YFLogxK

U2 - 10.1055/s-2004-814152

DO - 10.1055/s-2004-814152

M3 - Article

VL - 35

SP - 794

EP - 801

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 11-12

ER -